GovWire

Research: Coronavirus (COVID-19) vaccines adverse reactions

Medicines Healthcare Products Regulatory Agency

January 13
10:33 2023

Coronavirus vaccine - summary of Yellow Card reporting

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need aversion of this document in a more accessible format, please email webupdates@mhra.gov.uk.Please tell us what format you need. It will help us if you say what assistive technology you use.

ARCHIVED - Coronavirus vaccine - summary of Yellow Card reporting

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need aversion of this document in a more accessible format, please email webupdates@mhra.gov.uk.Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

The MHRA has played an active role in responding to the coronavirus pandemic. In relation to COVID-19 vaccines, the MHRA has authorised their supply following a rigorous review of their safety, quality and efficacy. The clinical trials of COVID-19 vaccines have shown them to be effective and acceptably safe; however, as part of its statutory functions, the MHRA is responsible for monitoring these vaccines on an ongoing basis to ensure their benefits continue to outweigh any risks.

This is a requirement for all authorised medicines and vaccines in the UK. This monitoring strategy is continuous, proactive and based on a wide range of information sources, with a dedicated team of scientists reviewing information daily to look for safety issues or unexpected rare events.

This report summarises information received via the Yellow Card scheme and will be published regularly to include other safety investigations carried out by the MHRA under the COVID-19 Vaccine Surveillance Strategy.

This report covers the period up to and including 28 December 2022 for COVID-19 vaccines used from the beginning of Autumn 2022.

The MHRA has begun implementing a new enhanced format of data visualisations. This enables us to provide improvements in format, accessibility and data protection, while also providing more data than has been published previously. Since December 2022, COVID-19 vacc

Related Articles

Comments

  1. We don't have any comments for this article yet. Why not join in and start a discussion.

Write a Comment

Your name:
Your email:
Comments:

Post my comment

Recent Comments

Follow Us on Twitter

Share This


Enjoyed this? Why not share it with others if you've found it useful by using one of the tools below: